热景生物(688068) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥202,939,171.05, representing a decrease of 85.13% compared to the same period last year[5] - The net profit attributable to shareholders was ¥58,884,119.48, down 90.28% year-over-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥50,048,505.39, a decline of 91.68% compared to the previous year[5] - The net cash flow from operating activities was -¥242,784,347.60, reflecting a decrease of 506.75% year-over-year[5] - Basic and diluted earnings per share were both ¥0.66, down 89.97% from the previous year[6] - Total operating revenue for Q1 2023 was ¥202,939,171.05, a significant decrease of 85.2% compared to ¥1,364,354,033.74 in Q1 2022[20] - Net profit for Q1 2023 was ¥56,095,829.44, a decline of 90.9% compared to ¥615,406,620.35 in Q1 2022[21] - Basic and diluted earnings per share for Q1 2023 were both ¥0.66, down from ¥6.58 in Q1 2022[22] - The company reported a profit before tax of ¥69,257,895.56 for Q1 2023, down 90.5% from ¥730,908,929.23 in Q1 2022[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,703,810,950.64, a decrease of 5.01% from the end of the previous year[6] - Current assets totaled RMB 1,354,547,109.62, down from RMB 1,798,268,654.72, indicating a decrease of about 24.66%[18] - Cash and cash equivalents were reported at RMB 319,262,764.49, significantly lower than RMB 523,493,118.90 at the end of 2022, representing a decline of approximately 39.0%[17] - The company's accounts receivable increased to RMB 102,912,830.96 from RMB 95,801,252.50, marking an increase of about 7.3%[17] - Non-current assets rose to RMB 2,349,263,841.02 from RMB 2,101,003,185.10, reflecting an increase of approximately 11.8%[18] - The total liabilities decreased to RMB 1,200,000,000.00, down from RMB 1,300,000,000.00, indicating a reduction of about 7.69%[18] - Total liabilities as of Q1 2023 amounted to ¥300,508,546.72, down from ¥545,589,123.77 in the previous year[20] - The company reported a significant reduction in accounts payable, which decreased to RMB 156,534,160.80 from RMB 263,443,202.57, a decline of approximately 40.6%[18] Research and Development - The R&D investment totaled ¥33,864,932.96, a decrease of 26.36% compared to the previous year, while the R&D investment as a percentage of operating revenue increased by 13.32 percentage points to 16.69%[6] - Research and development expenses for Q1 2023 were ¥33,864,932.96, a decrease of 26.4% compared to ¥45,989,803.16 in Q1 2022[21] Market and Business Strategy - The company attributed the significant decline in revenue and profit to the reduced demand for COVID-19 antigen test kits as the pandemic situation improved[10] - The company is focusing on promoting routine clinical testing products, which have surpassed pre-pandemic levels and are experiencing rapid growth[10] - The company is focusing on expanding its market presence and developing new technologies, although specific figures were not disclosed in the report[16] Cash Flow and Investments - Cash inflow from operating activities in Q1 2023 was ¥163,459,229.15, a decrease of 84.8% from ¥1,075,385,948.77 in Q1 2022[24] - The net cash flow from operating activities was -$242.78 million, compared to $59.69 million in the previous year, indicating a significant decline in operational cash generation[25] - Total cash outflow from operating activities amounted to $406.24 million, down from $1.02 billion year-over-year[25] - Cash inflow from investment activities was $607.83 million, while cash outflow was $561.51 million, resulting in a net cash flow from investment activities of $46.32 million, a recovery from a negative $568.74 million last year[25] - The company reported a net decrease in cash and cash equivalents of $204.23 million, compared to a decrease of $509.60 million in the same period last year[26] - The ending balance of cash and cash equivalents was $318.98 million, down from $644.71 million year-over-year[26] - The company received $590.84 million in cash from investment recoveries, a decrease from $757.10 million in the previous year[25] - The cash paid for the acquisition of fixed assets and intangible assets was $126.98 million, compared to $82.74 million last year[25] Accounting and Reporting Changes - The company has implemented new accounting standards starting in 2023, which may affect financial reporting[26] - The report indicates that there are no significant changes in the company's financing or transfer business activities during the reporting period[15]